Esquejo, Ryan M.
Pfizer (United States)
2 papers on CoChatORCID 0009-0003-3996-8318
Most cited papers
- Verified
Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, et al. (2015) · Nature Communications
Diabetes, Cardiovascular Risks, and LipoproteinsPharmacogenetics and Drug Metabolism
Cited by 368
- Verified
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
Saxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 156
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free